ProfileGDS5678 / 1426259_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 77% 80% 79% 80% 81% 81% 84% 87% 78% 79% 80% 80% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.3849178
GSM967853U87-EV human glioblastoma xenograft - Control 25.2557977
GSM967854U87-EV human glioblastoma xenograft - Control 35.5967580
GSM967855U87-EV human glioblastoma xenograft - Control 45.7256679
GSM967856U87-EV human glioblastoma xenograft - Control 55.6731180
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.5539981
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6152181
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1808584
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6649887
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.4102378
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.4807379
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.7356180
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.6518980
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6019980